Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $68 from $63 and keeps a Hold rating on the shares. The firm believes that the guidance issued at its investor conference is achievable and accounts for growth challenges being faced and potential future catalysts.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Early notable gainers among liquid option names on December 4th
- Edwards Lifesciences sees FY25 adjusted EPS $2.40-$2.50, consensus $2.47
- Edwards Lifesciences backs FY24 constant currency sales growth of 8%-10%
- Edwards Lifesciences price target raised to $88 from $85 at Barclays
- Edwards Lifesciences price target raised to $80 from $75 at RBC Capital
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
